

Date: August 11, 2023

Head- Listing & Compliance
Metropolitan Stock Exchange of India Ltd. (MSEI),
4th Floor, Vibgyor Towers, Plot No. C 62,
G Block, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 098

Dear Sir,

Sub: Outcome of the Board Meeting held on today, 11th August 2023

Please note that the Board of Directors of the Company at its meeting held today, which commenced at 2.45 p.m. and concluded at 3.15 p.m. as inter alia transacted the following business (es):

1. Considered, approved and adopted the Un-audited Financial Results for the quarter ended 30th June, 2023. A copy of Un-audited Financial Results for the quarter ended 30th June, 2023 alongwith Limited Review Report of the Company is enclosed;

Kindly take the same on your record and oblige.

Thanking You,

For Jagadishwar Pharmaceutical Works Limited

Gunodhar Ghosh
Executive Director
(DIN: 08524622)

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd. Office: 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email ID: jpw ltd@yahoo.com Website: jagadishwarpharma.com Tel: +91 9163513015

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rupees In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.23	31.03.23	30.06.22	31.03.23
		Unaudited	Audited	Unaudited	Audited
	PART - I				
I	Income From Operations	-	-	-	-
II	Other Income	7.64	10.76	11.01	44.14
III	Total Income from Operations (I + II)	7.64	10.76	11.01	44.14
IV	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	2.77	-	2.77
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	(2.77)	-	(2.77)
	(d) Employee benefits expense	5.48	5.49	5.13	25.11
	(e) Depreciation and amortisation expense	-	-	-	-
	(f) Finance Cost	-	-	-	-
	(g) Other expenses	4.63	2.00	4.59	10.50
	Total Expenses	10.12	7.49	9.72	35.61
V	Profit (Loss) before Exceptional Items and Extra Ordinary Items and Tax (III-IV)	(2.48)	3.27	1.29	8.53
VI	Exceptional Items	-	-	-	-
VII	Profit / (Loss) from ordinary activities before Extra Ordinary Items and Tax (V-VI)	(2.48)	3.27	1.29	8.53
VIII	Extra Ordinary Items	-	-	-	-
IX	Net Profit / (Loss) Before Tax (VII-VIII)	(2.48)	3.27	1.29	8.53
X	Tax Expense :				
	(1) Current Tax	0.76	2.22	1.10	2.22
	(2) Deferred Tax	-	-	-	-
	Total Tax Expenses	0.76	2.22	1.10	2.22
XI	Net Profit / (Loss) for the period from continuing operations (IX-X)	(3.24)	1.05	0.19	6.31
XII	Profit/(Loss) for the period from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) for the period from discontinuing operations (after tax)	-	-	-	-
XV	Profit / (Loss) for the period (XI + XIV)	(3.24)	1.05	0.19	6.31
XVI	Other Comprehensive Income	-	13.41	-	13.41
XVII	Total Comprehensive Income	(3.24)	14.46	0.19	19.72
XVIII	Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02
XVIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	115.67
XX	Earnings Per Share (EPS)				
	(a) Basic	-	0.00	0.00	0.02
	(b) Diluted	-	0.00	0.00	0.02

Notes :

- 1 The figures for the corresponding previous periods have been restated / regrouped, wherever necessary, to make them comparable.
- 2 These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable .
- 3 The Audit Committee reviewed the above results. The Board of Directors at its meeting held on 11th August, 2023, approved the above results. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 4 The Company does not have any reportable segment as per Indian Accounting Standard "Operating Segment" (Ind AS-108). Accordingly,

For Jagadishwar Pharmaceuticals Works Ltd.



Gunodhar Ghosh

Gunodhar Ghosh

Director

(DIN : 08524622)

Date : 11/08/2023

Place: Kolkata



Review report to Impala Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 30th June 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **Rajesh U Shah & Associates**
Chartered Accountants



Rajesh Shah

Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 23056550B4ZFR19580



Place: Kolkata

Date: August 11, 2023